AI-Driven Pharmacogenomics: The Future of Personalized Medicine

This review examines the collaboration between artificial intelligence (AI) and pharmacogenomics, emphasizing its potential to revolutionize personalized medicine. By harnessing AI technologies, we can improve drug discovery, optimize treatment protocols, and ultimately enhance patient outcomes. Key findings indicate that while pharmacogenomics has deepened our understanding of how genetics affect drug responses, AI provides innovative solutions to existing challenges, enabling the development of more effective and tailored therapeutic strategies. AI technologies, including machine learning (ML), natural language processing (NLP), and deep learning, are becoming vital in healthcare by facilitating the analysis of large, complex datasets. These technologies enable predictive modeling, pattern recognition, and data-driven decision-making. In pharmacogenomics, AI can identify genetic patterns related to drug responses that traditional methods might miss. By integrating genomic data with clinical information, AI enhances the accuracy of treatment plans, resulting in more individualized patient care. Pharmacogenomics studies how an individual’s genetic composition influences their reaction to medications, which is crucial for personalized medicine. This approach allows healthcare professionals to customize treatments to improve effectiveness and minimize adverse effects. The combination of AI and pharmacogenomics is set to revolutionize treatment strategies, leading to therapies that are more effective and aligned with individual genetic characteristics. As research and technology continue to progress, the potential for AI-driven pharmacogenomics to improve patient care and outcomes becomes increasingly feasible.